Navigation Links
Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2011, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco, California. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic indication and use; the potential FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
Breaking Medicine News(10 mins):